⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363789 | 1.00 | — | — | |
| SCHEMBL7114778 | 1.00 | — | — | |
| SCHEMBL12056882 | 0.96 | — | — | |
| SCHEMBL16743051 | 0.83 | — | — | |
| SCHEMBL12027171 | 0.81 | — | — | |
| SCHEMBL733773 | 0.78 | — | — | |
| SCHEMBL670442 | 0.76 | — | — | |
| SCHEMBL11528303 | 0.76 | — | — | |
| SCHEMBL8155745 | 0.76 | — | — | |
| SCHEMBL5924261 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190071454-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-10189859-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2019-01-29 | — | — | US | disclosed |
| CN-108329246-A | Pyrrolidinyl urea and pyrrolidinyl thiourea compound as TRKA kinase inhibitors | 阵列生物制药公司 | 2018-07-27 | — | — | CN | disclosed |
| CN-108174603-A | 1-heteroaryl-indoline-4-carboxamides as GPR52 modulators for the treatment or prevention of disorders related thereto | 阿芮纳制药有限公司 | 2018-06-15 | — | — | CN | disclosed |
| CN-105130967-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compound as TRKA kinase inhibitors | 阵列生物制药公司 | 2018-04-17 | — | — | CN | disclosed |
| US-20170066782-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2017-03-09 | — | — | US | disclosed |
| WO-2015092819-A2 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5- AMINE | NEKTAR THERAPEUTICS (INDIA) PVT. LTD. (IN) | 2015-06-25 | — | — | WO | disclosed |
| US-7388020-B2 | Benzimidazol derivatives modulate chemokine receptors | ASTRAZENECA AB (SE) | 2008-06-17 | — | — | US | disclosed |
| US-20040116435-A1 | Benzimidazol derivatives modulate chemokine receptors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| EP-1373248-A1 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| US-6569873-B2 | Treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination | WYETH | 2003-05-27 | — | — | US | disclosed |
| US-20030055079-A1 | Azolidines as beta-3 adrenergic receptor agonists | WYETH | 2003-03-20 | — | — | US | disclosed |
| WO-2002074763-A9 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002074763-A1 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002006258-A1 | AZOLIDINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-1996024598-A1 | [4-HEXADECYL-3-METHOXY-BUTYL] PHOSPHONIC ACID AND ITS PROTEIN CONJUGATES USEFUL AS ANTI-CANCER AGENTS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1996-08-15 | — | — | WO | disclosed |